Drug Trial Radar · NCT02459080
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
619
Actual
Start
Sep 2015
Primary completion
Aug 2016
Study completion Sep 2016
Sponsor
- Lead sponsor
- Mylan Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Theravance Biopharma
- First posted
- Jun 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Trough FEV1 on Day 85Time frame: Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Allergy Associates Research Center (AARC)
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.